Skip to content

Applied research of acupuncture joint drugs bandage on allergic thinitis

Applied research of acupuncture joint drugs bandage on allergic thinitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001953
Enrollment
Unknown
Registered
2025-10-16
Start date
2025-12-19
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic rhinitis

Interventions

control group:Fluticasone Propionate Nasal Spray ( Fushuliang ) Nose Spray
test team:Acupoint application of acupuncture and medicine

Sponsors

Xiyuan Hospital of CACMS
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Age 18-65 years old ( including boundary age ) regardless of gender ; 2.In line with the diagnostic criteria of allergic rhinitis TCM syndrome differentiation is in line with lung qi deficiency and cold syndrome the degree of disease VAS score is mild to moderate ( 1-7 points ) ; 3.There was no standard treatment for the disease in the past 7 days ; 4.Continuing to publish the author in the past week ; 5. Volunteers signed informed consent.

Exclusion criteria

Exclusion criteria: 1.Subjects with severe nasal diseases, a history of nasal surgery within 1 year, acute or chronic systemic diseases, severe infections, poorly controlled diabetes, malignant tumors, or long-term use of nasal decongestant sprays; 2.Subjects with abnormal functions of vital organs such as the heart, liver, or kidneys (Note: those with liver or kidney function test results exceeding 1.5 times the normal range within the past 3 months); 3.Subjects with skin lesions at the application site, such as scars, ulcers, etc.; 4.Subjects with autonomic nervous system disorders accompanied by abnormal sweat secretion; 5.Pregnant or lactating women; 6.Subjects with a known allergy to the trial drugs; 7.Subjects with drug resistance to antihistamines; 8.Subjects currently participating in other clinical studies or receiving similar external therapy interventions; 9.Subjects currently using glucocorticoid drugs, or undergoing regular immunotherapy or biologic agent treatment

Design outcomes

Primary

MeasureTime frame
symptoms rating scales;

Secondary

MeasureTime frame
Nasal symptoms visual analogue scale ( VAS score );onset time;Nasal endoscopy examination;Nasal conjunctivitis quality of life questionnaire ( RQLQ );

Countries

China

Contacts

Public ContactZi Mingjie

Xiyuan Hospital of CACMS

drzimingjie@126.com13621052996

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026